KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Pulmonology / 2022 / Cilt: 24 - Sayı: 1

COPD and comorbidities in the Republic of Moldova

Alexandru Corlateanu
Serghei Covantsev
Eugenia Scutaru
Doina Rusu
Victor Botnaru
Olga Corlateanu
Nikolaos Siafakas
Sayfa
9–17
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The Charlson comorbidity index (CCI) had a medium negative correlation with the 6-minute walking test (r=–0.37, p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:BACKGROUND AND AIM: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide, and the majority of patients have at least one comorbid condition of clinical significance.
📊
Temel Bulgular & Veri:METHODS: The study was a prospective cohort study that included 435 patients with COPD from 2015 to 2017.
💡
Sonuç & Katkı:The Charlson comorbidity index (CCI) had a medium negative correlation with the 6-minute walking test (r=–0.37, p
🔬Tür:Araştırma Makalesi
📍Kapsam:2015 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

BACKGROUND AND AIM: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide, and the majority of patients have at least one comorbid condition of clinical significance. Therefore, we studied its prevalence and implication based on experience from the Republic of Moldova. METHODS: The study was a prospective cohort study that included 435 patients with COPD from 2015 to 2017. RESULTS: We found heart failure in 38.62% of the patients, hypertension in 50.11%, coronary artery disease in 23.45%, diabetes mellitus in 10.11%, renal failure in 1.15%, rheumatoid arthritis in 3.22%, depression in 4.83%, cognitive impairment in 4.37%, obesity in 29.89%, and cachexia in 3.22%. Only 24.65% of patients did not have comorbidities. One comorbidity was found in 23.73%, two in 24.19%, three or more in 27.42%. The Charlson comorbidity index (CCI) had a medium negative correlation with the 6-minute walking test (r=–0.37, p

🔖

Bu Makaleye Atıf Yap

Corlateanu, A., Covantsev, S., Scutaru, E., Rusu, D., Botnaru, V., Corlateanu, O., Siafakas, N. (2022). COPD and comorbidities in the Republic of Moldova. Eurasian Journal of Pulmonology, Cilt: 24 - Sayı: 1, 9–17. https://ajindex.com/articles/499829

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, manage- ment, and prevention of chronic obstructive lung disease 2017 Report. GOLD executive summary. Am J Respir Crit Care Med 2017;195:557–82
  2. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: A systematic analysis for the global burden of disease study 2015. Lancet Respir Med 2017;5:691–706
  3. Chen W, FitzGerald JM, Sin DD, Sadatsafavi M. Excess economic burden of comorbidities in COPD: A 15-year population-based study. Eur Respir J 2017;50:1700393
  4. Negewo NA, Gibson PG, Wark PA, Simpson JL, McDonald VM. Treatment burden, clinical outcomes, and comorbidities in COPD: An examination of the utility of medication regimen complexity index in COPD. Int J Chron Obstruct Pulmon Dis 2017;12:2929–42
  5. Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Siafakas N. Prevalence and burden of comorbidities in chronic obstructive pulmonary disease. Respir Investig 2016;54:387–96
  6. Dal Negro RW, Bonadiman L, Turco P. Prevalence of different co- morbidities in COPD patients by gender and GOLD stage. Mul- tidiscip Respir Med 2015;10:24
  7. Rogliani P, Brusasco V, Fabbri L, Ungar A, Muscianisi E, Barisone I, et al. Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary dis- ease. Expert Rev Respir Med 2018;12:103–12
  8. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319–38
  9. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948–68
  10. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Men- dez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary dis- ease. N Engl J Med 2004;350:1005–12
  11. Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, Tordera MP, Sánchez PR. Severe exacerbations and BODE index: Two indepen- dent risk factors for death in male COPD patients. Respir Med 2009;103:692–9
  12. Sundh J, Janson C, Lisspers K, Ställberg B, Montgomery S. The dys- pnoea, obstruction, smoking, exacerbation (DOSE) index is predic- tive of mortality in COPD. Pr